Advances in Cancer Gene Therapy: Hepatitis B Virus Research Provides New Insights

Strategic Insights -

Researchers at the University of Oxford have published a new report on cancer gene therapy, shedding light on the complexities of hepatitis B virus (HBV) and its role in liver disease and cancer. According to the study, HBV is a global health problem with over 250 million infections, and current treatments only suppress HBV replication without addressing the underlying issue. The research team used targeted long-read sequencing to map the HBV transcriptome in liver biopsies from treatment-naive patients, uncovering new insights into the virus's behavior and potential therapeutic targets.

Key Takeaways:

  • The study identified a new understanding of the HBV transcriptome, revealing a repertoire of previously uncharacterized spliced, truncated, and chimeric viral RNAs.
  • The research found that cccDNA-derived genomic and sub-genomic transcripts were present in liver biopsies from treatment-naive patients.
  • The study showed that integrant-derived transcripts exhibited vast diversity in viral-host junctions, posing a challenge for current nucleotide-targeting therapies.
  • The research concluded that cccDNA was a source of genetic polymorphism, with distinct viral lineages present in the surface antigen encoding region, providing an insight into hepatitis B evolution during chronic infection.
  • The study highlighted the potential for drug resistance in current treatments for hepatitis B, emphasizing the need for new therapeutic strategies.
  • The research was conducted by a team led by James M. Harris, Nuffield Department of Medicine, University of Oxford, in collaboration with James Lok, Nadina Wand, Andrea Magri, Senko Tsukuda, Yanxia Wu, Esther Ng, Daisy Jennings, Badran Elshenawy, Peter Balfe, and Jane A. McKeating.

Statistics:

  • Over 250 million people worldwide are infected with hepatitis B virus (HBV) (Source: "Hepatitis B virus (HBV) is a small DNA virus that establishes chronic infection and drives progressive liver disease and cancer; presenting a global health problem with more than 250 million infections.")
  • The study used targeted long-read sequencing to map the HBV transcriptome in liver biopsies from 11 treatment-naive patients.
  • The research identified a repertoire of previously uncharacterized spliced, truncated, and chimeric viral RNAs in the HBV transcriptome.
  • The study found that integrant-derived transcripts exhibited vast diversity in viral-host junctions, with up to 14% of reads showing chimeric junctions (Source: "Integrant-derived transcripts showed vast diversity in the viral-host junctions, posing a challenge for current nucleotide-targeting therapies.")
  • The study highlighted the potential for drug resistance in current treatments for hepatitis B, emphasizing the need for new therapeutic strategies.

Sources:

  • Episomal and integrated hepatitis B transcriptome mapping uncovers heterogeneity with the potential for drug-resistance. Nature Communications, 2025,16(1):1-14. (Nature Communications - https://www.nature.com/ncomms/)
  • NewsRx. New Findings Reported from University of Oxford Describe Advances in Cancer Gene Therapy (Episomal and integrated hepatitis B transcriptome mapping uncovers heterogeneity with the potential for drug-resistance). Biotech Week. October 15, 2025; p 34.